


09-10-02 EXPRESS MAIL LABEL No. EL74281945  
 PTO/SB/21 (08-00) 163

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <h1>TRANSMITTAL FORM</h1> <p>to be used for all correspondence after initial filing)</p>	Application Number	09/874,512	TECH CENTER 1600/2900 SEP 12 2002 RECEIVED
	Filing Date	06/05/2001	
	First Named Inventor	David H. Sachs	
	Group Art Unit	1632	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	Attorney Docket Number	59056.260	

## ENCLOSURES (check all that apply)

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input checked="" type="checkbox"/> Amendment / Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)<br><input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>- Postcard |
|--|---|---|

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Michael J. Twomey

Signature

*Michael J. Twomey*

Date

09/09/2002

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

09/09/2002


Typed or printed name

Signature

Date

09/09/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT

Atty. Docket No. MGH-0676.7

(059056-260)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Sachs

SERIAL NUMBER: 09/874,512

ART UNIT: 1632

FILING DATE: June 5, 2001

EXAMINER: Unknown

TITLE: Allogeneic and Xenogeneic  
Transplantation

RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

## SECOND PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Second Preliminary Amendment is being filed prior to the receipt of a first Office Action in the above-identified application, and is not in response to any outstanding action or notice from the Patent Office.

## AMENDMENT

In the Claims

Please cancel claims 1-18 and add new claims 19-23 as follows:

- 
19. (New) A kit comprising an anti-CD2 antibody or an antigen-binding fragment thereof in a pharmaceutically acceptable carrier; and an immunosuppressive agent.
20. (New) The kit of claim 19, wherein the anti-CD2 antibody is monoclonal.
21. (New) The kit of claim 19, wherein the antibody or antigen binding fragment comprises BTI-322.
22. (New) The kit of claim 19, wherein the anti-CD2 antibody binds an epitope also recognized by BTI-322.
23. (New) The kit of claim 19 wherein the immunosuppressive agent is selected from the group consisting of cyclosporine, FK-506, and rapamycin.
- 

B'